PubMed Health⌕ Search

Biomedical subjects

F Rutledge

Publications and source records attributed to F Rutledge.

13 recordsLinked to original sources
PubMed1979

Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.

Hexamethylmelamine (HMM), NSC 13875, a synthetic agent structurally related to triethylenemelamine, has clinical antitumor activity and a role in the treatment of ovarian cancers of epithelial origin. Fifty-four patients, with International Federation of Gynecology and Obstetrics Stage III or IV carcinomas, previously untreated with chemotherapy or irradiation therapy, were treated with HMM (8 mg/kg/day) as a single agent at the M. D. Anderson Hospital and Tumor Institute in Houston, Texas, between January, 1973, and May, 1976. The response end points analyzed were complete plus partial response rate, duration of remission, and survival time. The complete and partial responses were verified whenever possible by "second-look" operation. Seventeen patients (31.8%) responded to HMM and three had no evidence of cancer, determined by multiple biopsies at second-look operation. Gastrointestinal, hematologic, and nervous system toxic effects were severe in 10 patients, requiring discontinuation of HMM. This study shows that HMM can induce a complete response and provide an extended disease-free interval without maintenance chemotherapy.

Adult↗
PubMed1978

Transfer factor and possible applications in gynecology.

Dialyzable transfer factor (TFd) is reviewed against its historical background, preparation methods, physiochemical properties, possible mechanisms of action, pharmacology, and clinical studies, including several areas relating to gynecology. The possible role of TFd as an adjunct in the treatment of cancer is discussed. The discussion centers on gynecologic cancer in several patients who have received TFd. The difficulties and future possibilities for this modality of treatment are considered.

Animals↗
PubMed1978

The treatment for dysgerminoma of the ovary.

Thirty-six patients with pure dysgerminoma of the ovary were treated at the University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute between 1947 and 1974. Twenty-six of these patients had their initial surgery at the M.D. Anderson Hospital or were referred to the M.D. Anderson Hospital shortly after surgery at another hospital. The remaining 10 were referred after developing a recurrence of their tumor. Five of the 26 patients who were treated initially at the M.D. Anderson Hospital had only a unilateral salpingo-oophorectomy and are alive and well at the present time. The remaining 31 patients have received postoperative radiotherapy. Ninety-two percent of the patients receiving initial treatment at M.D. Anderson Hospital, and seventy percent of those referred for treatment after recurrence, are surviving at the present time without evidence of disease. The selection of treatment for the individual patient is discussed.

Adolescent↗
PubMed1978

Characterization of an ovarian carcinoma cell line.

A long-term ovarian carcinoma cell line is described in terms of its morphology, original histopathology, electron microscopic features and chromosome features before and after transplantation into an athymic nude mouse. The microscopic features of the tumor nodule grown in the nude mouse are compared with the original pathology. Epithelial characteristics of the cells were maintained in culture and after retrieval from the nude mouse. Three markers were identified in all karyotypes and trisomy was noted in chromosomes 1, 2, 3, 6, 11, 12, 16, and X and monosomy of 17 and 21.

Adenocarcinoma↗
PubMed1976

Second-look operation in ovarian carcinoma: postchemotherapy.

One hundred and three patients with advanced ovarian cancer underwent a second-look operation following chemotherapy. Patients should have ten or more courses of chemotherapy before second-look operation. Those patients with no evidence of disease at second laparotomy should discontinue their chemotherapy. Patients who continued chemotherapy after the second-look operation did better than those who were treated with radiation after surgery. Only patients with clinical remission benefit from the second-look procedure. Advantages of second-look operations following chemotherapy are discussed.

Dose-Response Relationship, Drug↗
PubMed1976

Primary carcinoma of the female urethra.

The clinical and morphological features in 81 cases of carcinoma of the female urethra were reviewed. The over-all 5 and 10-year survival rate for the entire group was 32 per cent. Survival expectations for patients with squamous carcinoma, transitional cell carcinoma and adenocarcinoma were similar when analyzed according to stage and all cell types appeared to respond equally to irradiation. Prognosis was related directly to the clinical stage of the disease. A plea is made for more accurate assessment of the disease status. The high incidence of local recurrence noted for all forms of single modality therapy (46 to 64 per cent) suggests the need for clinical trials with combination preoperative irradiation followed by definitive surgical procedures.

Adenocarcinoma↗
PubMed1975

Advances in chemotherapy for gynecologic cancer.

Considerable progress is being made in the chemotherapy of some gynecologic cancers. A random study comparing postoperative irradiation therapy with chemotherapy shows the two to be equally effective. Chemotherapy has the advantages of added safety and of being much less expensive for the patient. Postoperative chemotherapeutic treatment with VAC of patients with embryonal carcinoma of the ovary can prevent recurrence of this frequently fatal tumor. In some patients with advanced embryonal carcinoma of the ovary, chemotherapy with VAC may produce permanent remissions. Combined irradiation and chemotherapy and vincristine and actinomycin-D may be curative for some patients with advanced sarcomas in the pelvis or abdomen. This treatment combination is associated with severe complications; however, some are preventable.

Adolescent↗